Bolder BioTechnology says MS drug candidate could be used for COVID-19
BOULDER — Eight-person drug development outfit Bolder BioTechnology Inc. said its multiple sclerosis drug candidate showed early promise as a potential treatment for COVID-19.
The Boulder company said Tuesday that the drug candidate designated as BBT-032 was able to inhibit 85% to 100% of COVID-19 viral replication at low doses when tested on healthy cells within a petri dish.
BBT-032 is part of a class of drugs known as interferons, which generally induce cells to create proteins that fight viral infections and reduce inflammation caused by diseases like AIDS, hepatitis C and certain types of cancer.
Bolder…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
BOULDER — Even with the COVID-10 pandemic several years in the rearview mirror, it remains…
-
Biopharmaceutical company AmideBio LLC has received a $1.93 million grant from the federal government for…
-
Boulder Community Health this month became the first facility in Colorado to offer patients a…
-
Columbine Health Systems will host Dementia Week, a series of free events devoted to educating…
